Canadian Investment Regulatory Organization Trading Halt - ATY.RT Français
Company: Atico Mining Corporation
TSX-Venture Symbol: ATY.RT
All Issues: No
Reason: Pending Delisting
Halt Time (ET): 12:00 PM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions
For further information about CIRO's trading halt policy, please see Trading Halts & Timely Disclosure at www.ciro.ca under the Markets tab. Please note that CIRO staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about CIRO, contact CIRO's Complaints & Inquiries team by submitting a Secure Form located on our contact page at www.ciro.ca or dialing 1-877-442-4322 (Option 1). For company-related enquiries, please contact the company directly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
21 minutes ago
- Cision Canada
Decision Notice - CIRO Hearing Panel issues Reasons for Decision in the matter of Jonathan Thomas Jones Français
VANCOUVER, BC, /CNW/ - Following a settlement hearing held on May 30, 2025, pursuant to the Investment Dealer and Partially Consolidated Rules, a hearing panel of the Canadian Investment Regulatory Organization (CIRO) issued its reasons for decision on July 10, 2025. The hearing panel's reasons for decision are available at: Re Jones 2025 CIRO 34 In their reasons for decision, the hearing panel found that Jonathan Jones traded in a security by means other than the entry of an order on a marketplace and confirmed a fine of $21,000 and costs of $2,000 imposed as part of the settlement. At all material times, Jonathan Jones conducted business with Haywood Securities Inc. in the Vancouver, British Columbia area. Jonathan Jones is currently registered as a Dealing Representative with Leede Financial Inc. The Canadian Investment Regulatory Organization (CIRO) is the national self-regulatory organization that oversees all investment dealers, mutual fund dealers and trading activity on Canada's debt and equity marketplaces. CIRO is committed to the protection of investors, providing efficient and consistent regulation, and building Canadians' trust in financial regulation and the people managing their investments. For more information, visit All information about disciplinary proceedings relating to current and former member firms and individual registrants under the Investment Dealer and Partially Consolidated Rules (for investment dealers), the Mutual Fund Dealer Rules (for mutual fund dealers) and the Universal Market Integrity Rules (UMIR) is available on CIRO's website. Background information regarding the qualifications and disciplinary history, if any, of advisors currently employed by CIRO-regulated investment firms is available free of charge through the AdvisorReport service. Information on how to make dealer, advisor or marketplace-related complaints is available by calling 1-877-442-4322. CIRO investigates possible misconduct by its member firms and individual registrants. It can bring disciplinary proceedings which may result in sanctions including fines, suspensions, permanent bars, expulsion from membership, or termination of rights and privileges for individuals and firms. All other Inquiries: Complaints & Inquiries Secure form Toll-free (Canada/US) 1-877-442-4322 SOURCE Canadian Investment Regulatory Organization (CIRO)
Cision Canada
21 minutes ago
- Cision Canada
Robert Half named by Forbes as one of Canada's Best Recruiting and Temporary Staffing Firms 2025
TORONTO, July 22, 2025 /CNW/ - Global talent solutions and business consulting firm Robert Half has been named one of Canada's Best Professional Recruiting Firms, Executive Recruiting Firms, and Temporary Staffing Firms in Forbes ' inaugural ranking of Canadian staffing and recruiting firms. The rankings were produced in partnership with market research firm Statista. The lists are based on survey responses from more than 15,000 participants in Canada—composed of human resources managers, hiring managers, recruiters and employees who recently worked with a recruiting firm. The survey was conducted between mid-February and mid-April 2025. "Being named to Forbes' first list of Canada's best recruiting companies is an honour, and makes us enormously proud", said David King, Senior Managing Director, Robert Half, Canada and South America. "Receiving this recognition underscores the importance we place on being a trusted advisor, providing access to world-class talent, diverse hiring solutions for our clients and the professionals we represent, as well as leadership within the larger industry." Robert Half connects companies with skilled talent and helps job seekers find roles from entry-level to executive positions, on both contract and permanent bases. Through its award-winning AI capabilities, the company has enhanced the candidate discovery, assessment and selection process, increasing its ability to staff critical roles faster. Robert Half is also recognized by Fortune as one of the 2025 World's Most Admired Companies. Robert Half is among a select group of companies to be honoured as a Fortune Most Admired Company for 28 consecutive years and is the only in its industry to achieve this distinction. About Robert Half Robert Half is the world's first and largest specialized talent solutions firm that connects opportunities at great companies with highly skilled job seekers. Offering contract and permanent placement solutions in the fields of finance and accounting, technology, marketing and creative, legal, and administrative and customer support, Robert Half has more than 300 locations worldwide. Robert Half is the parent company of Protiviti ®, a global consulting firm that provides internal audit, risk, business and technology consulting solutions. Robert Half, including Protiviti, has been named to the Fortune ® Most Admired Companies ™. Explore our comprehensive solutions, research and insights at
Cision Canada
an hour ago
- Cision Canada
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB, July 22, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY." As previously announced, the Company was notified by Nasdaq on February 13, 2025, that the Company's common shares failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. According to the Compliance Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company's common shares has been at or above $1.00 per share for 10 consecutive business days, from July 8, 2025, through July 21, 2025, and the matter is now closed. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]
